News
Updates on Alsonex's research into new treatments for neurodegenerative disease.
Remembering Neale Daniher
Alsonex notes with sadness the passing of Neale Daniher, co-founder of FightMND, whose support helped advance ALS-205 from preclinical evaluation into human clinical trials.
Read announcement ↗Alsonex to Attend BIO26 in San Diego
Alsonex will attend the BIO International Convention 2026 (BIO26), held 22–25 June 2026 in San Diego, with Paul Field representing the company in meetings with prospective partners and investors.
Read announcement ↗Neuroinflammation and Neurodegenerative Disease
New treatments are urgently required to slow the progression of neurodegenerative disease, an area of intensive research within the pharmaceutical industry.
Read announcement ↗Company Update
Through its research, Alsonex aspires to make a meaningful impact on neurodegenerative disease — with a first interest in MND/ALS and a growing interest in Parkinson's and Alzheimer's Disease.
Read announcement ↗Media Enquiries
Alsonex is a biotech company creating treatments for motor neurone disease and other neurodegenerative disorders.
Read announcement ↗